articleTo ensure that clinicians buy into biosimilars, it is important…
18 February 2021 | By Nikki Withers (European Pharmaceutical Review)
To ensure that clinicians buy into biosimilars, it is important that they understand how products are analysed and compared to the originator molecules. Dr Fraser Cummings and Jonathan Sweeting discussed this issue at a recent virtual roundtable event, where they highlighted the complexities of biosimilar development pathways and approval processes. Here, Nikki Withers shares the…
